Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H22N2S |
Molecular Weight | 322.467 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(C1CN2CCC1CC2)N3C4=CC=CC=C4SC5=C3C=CC=C5
InChI
InChIKey=HOKDBMAJZXIPGC-UHFFFAOYSA-N
InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
Molecular Formula | C20H22N2S |
Molecular Weight | 322.467 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01071
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01071
Mequitazine (PRIMALAN®) is a phenothiazine derivative and a histamine H1-receptor antagonist. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14987305
Curator's Comment: It was concluded that mequitazine is mildly sedating. The effects of mequitazine are comparable to those of other second-generation antihistamines, in that it causes mild driving impairment, particularly at higher doses.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3943 Sources: https://www.drugbank.ca/drugs/DB01071 |
280.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date1984 |
|||
Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date1984 |
|||
Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date1984 |
|||
Primary | PRIMALAN Approved UseAntihistamine for the treatment of allergic conditions such as hay fever, perennial rhinitis, urticaria, pruritis of allergic origin and allergic reactions associated with insect bites and stings. Launch Date1984 |
Sample Use Guides
The usual dose for adults is one 5 mg tablet to be taken orally twice a day, although in elderly patients (over 65 years) caution should be used.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/41044
The affinity of mequitazine for H1 receptors in guinea pigs was compared with that of classical sedative antihistamines ((+)-chlorpheniramine and promethazine). In vitro determinations of Ki values of [3H]mepyramine binding in the brain reveal that mequitazine is 15 to 20 times less potent than (+)-chlorpheniramine and promethazine (Ki value was 280 nM, 12 nM and 17 nM, respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:17 GMT 2023
by
admin
on
Fri Dec 15 15:22:17 GMT 2023
|
Record UNII |
Y463242LY2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR06AD07
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
||
|
WHO-ATC |
R06AD07
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C006069
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
m7201
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8023262
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
29528
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
29216-28-2
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
Y463242LY2
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
C170162
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
MEQUITAZINE
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
303612
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
DB01071
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
4066
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
3672
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908311
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
249-521-7
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
1707
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
SUB08766MIG
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY | |||
|
100000081707
Created by
admin on Fri Dec 15 15:22:17 GMT 2023 , Edited by admin on Fri Dec 15 15:22:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |